Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
2017 ◽
Vol 20
(1)
◽
pp. 332
◽
1988 ◽
Vol 46
◽
pp. 382-383
1992 ◽
Vol 50
(1)
◽
pp. 486-487
1994 ◽
Vol 52
◽
pp. 274-275
2013 ◽
Vol 22
(3)
◽
pp. 107-117
◽
1996 ◽
Vol 26
(3)
◽
pp. 308-315
◽
1997 ◽
Vol 27
(2)
◽
pp. 218-224
◽
1997 ◽
Vol 27
(8)
◽
pp. 926-931
◽
Keyword(s):